Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02685605 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02685605 · ClinicalTrials.gov record · last posted 2025-10-14

Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme

Study acronym: INTRAGO-II
StatusActive, Not Recruiting
PhasePhase 3
Started2016-12-09
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 14, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to standard radiochemotherapy.

Amendment record 22 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 22 times since 2016-02-14; most recent amendment 2025-10-10. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-06-28
Status change Recruiting→Active, Not Recruitingv21
2016-06-08
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT02685605
Lead Sponsor Universitätsmedizin Mannheim
Collaborators: Carl Zeiss Meditec AG, University of California, Los Angeles
Conditions Glioblastoma
Enrollment 314 participants
Start Date 2016-12-09
Primary Completion 2025-11 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-10-14